UroGen Pharma (URGN) said Tuesday that new data from a long-term, follow-up study showed that patients with urothelial cancer who achieved a complete response to primary treatment with the company's Jelmyto chemoablation therapy had a median duration of response of 47.8 months following their initial treatments.
The study enrolled 71 patients with low-grade, upper tract urothelial cancer, including 41 people who achieved complete response after being treated with Jelmyto.
The company said prior research indicated the primary treatment goal for the patient population would be managing relapse and preserving organ function because of the low risk of disease progression.
UroGen also said that investigators were continuing to explore Jelmyto's potential to treat urothelial cancer and are now enrolling participants from the company's uTRACT registry to gather longitudinal data about its real-world usage.
Price: 12.22, Change: -0.26, Percent Change: -2.08
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。